246m reasons to invest in China equities

At 130 million, China's population of citizens aged 65+ is the world's largest and it will grow to 246 million by 2030. Find out why this may be a golden investment opportunity.

14 Nov 2018

IKEA has a problem in China, but not from a lack of visitors.

It's because of old people. Specifically, the thousands who set up in the in-store cafes to meet friends, drink coffee, and date suitors. They aren't buying furniture, but they are going to IKEA because there's no space left in China's community centers as China's elderly population expands.

Greying population, Golden opportunity

Numbering 130 million in 2015, China's 65+ population is the world's largest and is forecasted to grow to 246 million by 2030, 3 times Germany's total population (1).

But while it’s challenging for IKEA to monetize its veteran visitors, we don't see it as a problem for companies in other sectors, in fact we believe that it’s a golden opportunity.

That's particularly true for the insurance sector, where life insurance premium sales grew 24% y-o-y to USD 309bn in 2017 , and overall premiums are forecast to grow 11.8% p.a. between 2017 and 2022 (2) .

Geoffrey Wong, UBS AM's Head of Emerging Markets and Asia Pacific Equities, says that 'the social security system (in China) is probably too small for upper income households and they have to buy insurance' - so that means opportunities for private insurers offering the health, life, and pension insurance products sought by China's increasingly affluent classes.

Health care spending has to increase

At the same time, Geoffrey says that, 'health care spending has to increase….China health care spending is very small compared to Europe and the US, and as population ages it has to catch up.'

And that's an opportunity for sectors like pharmaceuticals and medical services. More old people means more age-related disease cases - 150.6 million cases of diabetes estimated by 2040 (3) - that supports a sales pipeline forecast to take total health care sector revenues in China from USD 780bn in 2017 to USD 2.5trn by 2030 (4).

For fundamentals to investment decision

But knowing fundamentals is one thing, it's another to identify companies positioned to benefit -and that's where the UBS AM team of China equity specialists looks to make the difference.

Their fundamentals-based approach seeks to identify companies with the business models, management and product quality to lead over the long-term.

And judging by their conviction in the long-term prospects for health care and insurance sectors, we believe that our China Opportunity Equity Fund strategy is well set for the future.

Important legal information

To proceed, please confirm that you are a professional / qualified / institutional client and investor.

Views and opinions expressed are presented for informational purposes only and are a reflection of UBS Asset Management’s best judgment at the time a report or other content was compiled. UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. The information and opinions contained in the content of this webpage have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any errors or omissions. All such information and opinions are subject to change without notice but any obligation to update or alter forward-looking statement as a result of new information, future events, or otherwise is disclaimed. Source for all data/charts, if not stated otherwise: UBS Asset Management.
Any market or investment views expressed are not intended to be investment research. Materials have not been prepared to address requirements designed to promote the independence of investment research and are not subject to any prohibition on dealing ahead of the dissemination of investment research. The information contained in this webpage does not constitute a distribution, nor should it be considered a recommendation to purchase or sell any particular security or fund. The materials and content provided will not constitute investment advice and should not be relied upon as the basis for investment decisions. As individual situations may differ, clients should seek independent professional tax, legal, accounting or other specialist advisors as to the legal and tax implication of investing. Plan fiduciaries should determine whether an investment program is prudent in light of a plan's own circumstances and overall portfolio. A number of the comments in the content of this webpage are considered forward-looking statements. Actual future results, however, may vary materially. Past performance is no guarantee of future results. Potential for profit is accompanied by possibility of loss. 
© UBS 2020 The key symbol and UBS are among the registered and unregistered trademarks of UBS.